Previous 10 |
F-star's antibody engineering platform is seemingly undervalued with comparable companies worth billions of dollars in equity value. The company has an exciting pipeline of early immuno-therapy clinical assets from F-star's recent pivot, 2 years ago, to internal drug development. ...
AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities. L...
The Trianni Mouse ® , AbCellera’s technology for generating large databases of human antibodies for drug discovery programs, is granted United States patent AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-genera...
AbCellera Biologics (ABCL) perks 2% premarket after Peter Thiel discloses 5.3% stake or holding of ~14.36M shares of the company.Mr. Thiel serves as a board member of the company and will be involved in reviewing transactions that may result in operational, strategic, financial or g...
Gainers: [[MGNI]] +15.1%. [[SCPS]] +11.4%. [[OCN]] +10.5%. [[CLNE]] +6.9%. [[AMTX]] +4.7%.Losers: [[VYGR]] -11.9%. [[YCBD]] -11.4%. [[SPPI]] -9.4%. [[AHT]] -9.0%. [[ABCL]] -8.7%. For further details see: MGNI, SCPS, YCBD and SPPI among after-hours movers
Study will provide real-world data to evaluate the effectiveness of bamlanivimab in reducing COVID-19 hospitalizations in a high-risk population AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody developed through AbCellera’s collabor...
Expectations are coming in for 2021. Despite the strong recent gains and record valuations, analysts and investors are expecting even more upside based on "the new normal". The IPO market has proven to be an extremely valuable indicator for future returns. Investors are clearly missin...
AbCellera Biologics Inc. (“AbCellera”) (Nasdaq: ABCL), a technology company that aims to become the centralized operating system for next-generation antibody discovery, today announced the closing of its initial public offering of 27,772,500 common shares at a price to the...
News, Short Squeeze, Breakout and More Instantly...
AbCellera Biologics Inc. Company Name:
ABCL Stock Symbol:
NASDAQ Market:
AbCellera Biologics Inc. Website:
AbCellera (Nasdaq: ABCL) will announce its second quarter 2024 financial results on Tuesday, August 6, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link t...
2024-06-13 05:40:00 ET Discovering new drugs can be a lucrative endeavor, but things aren't working out lately for AbCellera Biologics (NASDAQ: ABCL) . Shares of this unusual biotech stock are down by about 57% from the high water mark they set last summer. The steep losses migh...
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 12:20 p.m. Pacific Time (3:20 p.m. Eastern Time). A live audio webcast of the presentation may be accessed throug...